Mitesco (MITI) 10-K 17 Apr 17 2016 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2016	Jun. 30, 2016
Document and Entity Information:
Entity Registrant Name	True Nature Holding, Inc.
Document Type	10-K
Document Period End Date	Dec. 31, 2016
Trading Symbol	tnty
Amendment Flag	false
Entity Central Index Key	802,257
Current Fiscal Year End Date	--12-31
Entity Common Stock, Shares Outstanding	17,436,666
Entity Public Float		$ 2,801,494
Entity Filer Category	Smaller Reporting Company
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	No
Document Fiscal Year Focus	2,016
Document Fiscal Period Focus	FY

TRUE NATURE HOLDING, INC. - Con

TRUE NATURE HOLDING, INC. - Consolidated Balance Sheets - USD ($)		Dec. 31, 2016	Dec. 31, 2015
Current Assets:
Cash			$ 28,185
Prepaid expenses and other current assets		$ 1,875	17,000
TOTAL CURRENT ASSETS		1,875	45,185
Total Assets		1,875	45,185
Current Liabilities:
Accounts payable		589,229	414,463
Accounts payable - related party		106,866
Accrued interest		31,021	14,918
Accrued liabilities		84,488	13,325
Convertible notes payable, in default		256,270	122,167
Total Current Liabilities		1,067,874	564,873
TOTAL LIABILITIES		1,067,874	564,873
COMMITMENTS AND CONTINGENCIES
STOCKHOLDERS' DEFICIT
Preferred stock	[1]
Common stock	[2]	174,367	117,650
Additional paid-in capital		4,261,748	3,917
Stock payable		20,000
Accumulated deficit		(5,522,114)	(641,255)
Total Stockholders' Deficit		(1,065,999)	(519,688)
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT		$ 1,875	$ 45,185
[1]	$0.01 par value; 100,000,000 shares authorized, none issued and outstanding as of December 31, 2016 and 2015
[2]	$0.01 par value, 500,000,000 shares authorized, 17,436,666 and 11,765,000 shares issued and oustanding, respectively.

Statement of Financial Position

Statement of Financial Position - Parenthetical - $ / shares	Dec. 31, 2016	Dec. 31, 2015
Statement of Financial Position
Preferred Stock, Par Value	$ 0.01	$ 0.01
Preferred Stock, Shares Authorized	100,000,000	100,000,000
Preferred Stock, Shares Issued	0	0
Preferred Stock, Shares Outstanding	0	0
Common Stock, Par Value	$ 0.001	$ 0.001
Common Stock, Shares Authorized	500,000,000	500,000,000
Common Stock, Shares Issued	17,436,666	11,765,000
Common Stock, Shares Outstanding	17,436,666	11,765,000

TRUE NATURE HOLDING, INC. - Co4

TRUE NATURE HOLDING, INC. - Consolidated Statements of Operations and Comprehensive Loss - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
OPERATING EXPENSES
Selling, general and administrative	$ 4,405,163	$ 64,756
Total Operating Expenses	4,405,163	64,756
Operating Loss from Continuing Operations	(4,405,163)	(64,756)
Interest expense	(269,367)	(896)
Loss on liability conversion to common shares	(206,329)
Net Loss from Continuing Operations	(4,880,859)	(65,652)
Discontinued Operations:
Net loss from discontinued operations, net of tax		(337,362)
Other comprehensive gain, net of tax		24,815
Comprehensive Loss from Discontinued Operations		(312,547)
Net loss	(4,880,859)	(403,014)
Comprehensive Loss	$ (4,880,859)	$ (378,199)
Net Loss from Continuing Operations Per Share - Basic and Diluted	$ (0.35)	$ (0.11)
Net loss from Discontinued Operations Per Share - Basic and Diluted	0	(0.55)
Net Loss Per Share - Basic and Diluted	$ (0.35)	$ (0.66)
Weighted Average Number of Shares Outstanding During the Period - Basic and Diluted	13,760,888	612,053

TRUE NATURE HOLDING, INC. - Co5

TRUE NATURE HOLDING, INC. - Consolidated Statement of Stockholders' Equity - USD ($)	Preferred Stock	Common Stock	Additional Paid-in Capital	Accumulated Comprehensive Loss	Stock Payable	Accumulated Deficit	Total
Balance, Value at Dec. 31, 2014		$ 5,480	$ 14,220,267	$ 17,974		$ (16,508,167)	$ 2,264,446
Balance, Shares at Dec. 31, 2014		542,605
Issuance of Trunity Holdings, Inc. preferred stock for acquisition of Newco4pharmacy, LLC, net of issuance costs, Value			106,900				106,900
Issuance of Trunity Holdings, Inc. preferred stock for acquisition of Newco4pharmacy, LLC, net of issuance costs, Shares	1,000
Exchange of Trunity Holdings, Inc. preferred stock for True Nature Holding, Inc. common stock, Value		$ 100,000	(100,000)
Exchange of Trunity Holdings, Inc. preferred stock for True Nature Holding, Inc. common stock, Shares	(1,000)	10,000,000
Common stock issued upon conversion of debenture prior to Spin-Out, Value		$ 883	141,631				142,514
Common stock issued upon conversion of debenture prior to Spin-Out, Shares		87,383
Discount related to issuance of debt with warrants and allocated fair value to beneficial conversion feature proior to Spin-Out			274,122				274,122
Stock compensation expense - discontinued operations			151,708				151,708
Gain on extinguishment of debt - discontinued operations			(1,867,428)				(1,867,428)
Foreign currency translation gain - discontinued operations				24,815			24,815
Common stock issued for conversion of debt, Value		$ 7,421	(7,421)
Common stock issued for conversion of debt, Shares		742,098
Common stock issued for satisfaction of payables, Value		$ 1,893	(1,893)
Common stock issued for satisfaction of payables, Shares		189,305
Common stock issued to Spin-Out Company, Trunity, Inc., Value		$ 2,033	(2,033)
Common stock issued to Spin-Out Company, Trunity, Inc., Shares		203,293
Shares issued and adjustments related to reverse split, Value		$ (60)	60
Shares issued and adjustments related to reverse split, Shares		316
Net loss from discontinued operations, net of tax						(337,362)	(337,362)
Spin-out adjustment			(12,915,913)	$ (42,789)		16,269,926	3,311,224
Stock compensation expense - continued operations			3,917				3,917
Net Loss						(65,652)	(65,652)
Balance, Value at Dec. 31, 2015		$ 117,650	3,917			(641,255)	(519,688)
Balance, Shares at Dec. 31, 2015		1,176,500
Common stock issued for conversion of debt, Value		$ 4,000	116,000				120,000
Common stock issued for conversion of debt, Shares		400,000
Net Loss						(4,880,859)	(4,880,859)
Sale of common stock, net of issuance costs, Value		$ 1,200	49,800				51,000
Sale of common stock, net of issuance costs, Shares		120,000
Beneficial conversion feature			67,062				67,062
Stock based compensation, Value		$ 40,700	3,337,035				3,377,735
Stock based compensation, Shares		4,070,000
Common stock and warrants issued and payable for debt discount, Value		$ 150	118,601		$ 20,000		138,751
Common stock and warrants issued and payable for debt discount, Shares		15,000
Common stock issued for the conversion of payables, Value		$ 1,067	569,333				580,000
Common stock issued for the conversion of payables, Shares		1,066,666
Balance, Value at Dec. 31, 2016		$ 174,367	$ 4,261,748		$ 20,000	$ (5,522,114)	$ (1,065,999)
Balance, Shares at Dec. 31, 2016		17,436,666

TRUE NATURE HOLDING, INC. - Co6

TRUE NATURE HOLDING, INC. - Consolidated Statements of Cash Flows - USD ($)		12 Months Ended
		Dec. 31, 2016	Dec. 31, 2015
Cash Flows from Operating Activities:
Net Loss		$ (4,880,859)	$ (65,652)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock based compensation		3,377,736	3,917
Loss on payable conversion		190,000
Debt discount amortization		249,592
Loss on debt conversion		16,329
Changes in operating assets and liabilities
Accounts payable		564,766	(4,316)
Prepaid expense		15,125	(17,000)
Accrued liabilities		74,028
Accounts payable - related parties		106,866
Accrued interest		16,909	4,336
Net cash used in operating activities		(269,508)	(78,715)
Cash Flows from Investing Activities:
Purchase of fixed assets
Net cash used in investing activities
Cash Flows from Financing Activities:
Repayment of convertible note		(67,677)
Proceeds from issuance of convertible note payable, net		258,000
Sale of common stock, net of issuance costs		51,000
Proceeds received from issuance of preferred stock	[1]		106,900
Net cash provided by financing activities		241,323	106,900
Discontinued Operations:
Operating activities			(287,725)
Investing activities			(108,812)
Financing activities			398,838
Net increase (decrease) in Cash and Cash Equivalents for Discontinued Operations			2,301
Net increase in Cash and Cash Equivalents for Continuing Operations		(28,185)	28,185
Cash, beginning of period		28,185	14,119
Cash to Spin Out			(16,420)
Cash, end of period			28,185
Non-cash Investing and Financing Transactions:
Beneficial conversion feature		67,062
Conversion of debt to common stock		103,671
Exchange of preferred stock for common stock	[2]		100,000
Common stock issued upon conversion of debenture prior to spin-out			142,514
Discount related to issuance of debt with warrants and allocated fair value to beneficial conversion feature prior to spin-out			274,122
Stock compensation expense - discontinued operations			151,708
Gain on extinguishment of debt - discontinued operations			(1,867,428)
Foreign currency translation gain - discontinued operations			24,815
Common stock issued for conversion of debt - discontinued operations			7,421
Common stock issued upon conversion of payables		390,000	1,893
Common stock issued to spin-out company	[3]		2,033
Shares issued and adjustments related to reverse split			60
Spin out adjustment			16,269,926
Liabilities assumed by company			$ 441,511
Discount cost related to issuance of debentures, warrants and convertible notes		$ 138,750
[1]	Proceeds received from issuance of preferred stock resulting from transaction with Newco4pharmacy
[2]	Exchange of Trunity Holdings, Inc. preferred stock for True Nature Holding, Inc. common stock
[3]	Common stock issued to spin-out company, Trunity, Inc.

Note 1 - Organization, Basis of

Note 1 - Organization, Basis of Presentation and Nature of Operations	12 Months Ended
	Dec. 31, 2016
Notes
Note 1 - Organization, Basis of Presentation and Nature of Operations	Note 1 – Organization, Basis of Presentation and Nature of Operations True Nature Holding, Inc. (the “Company”), previously known as Trunity Holdings, Inc., became a publicly-traded company through a reverse merger with Brain Tree International, Inc., a Utah corporation (“BTI”). BTI was incorporated on July 26, 1983 to specialize in the development of high technology products or applications including, but not limited to, electronics, computerized technology, new technological product fields, and precious metals. Trunity Holdings, Inc. was the parent company of the prior educational business, named Trunity, Inc., which was formed on July 28, 2009 through the acquisition of certain intellectual property by its three founders. True Nature Holding, Inc. is a Corporation organized under the Laws of Delaware with principal offices located in Atlanta, Georgia. On January 16, 2016, the Company changed the equity structure that included a reverse split of 1 for 101, such that all holders of 101 shares of common stock would then have 1 share and modified the Articles of Incorporation such that the Company now has 500,000,000 shares of common stock authorized and 100,000,000 of preferred stock authorized, and e) a change in the name of Trunity Holdings, Inc. to True Nature Holding, Inc. (there was no change in the stock symbol “TNTY”). The accompanying consolidated financial statements include the accounts of True Nature Holding, Inc. as December 31, 2016.

Note 2 - Summary of Significant

Note 2 - Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2016
Notes
Note 2 - Summary of Significant Accounting Policies	Note 2 – Summary of Significant Accounting Policies Basis of Accounting The consolidated financial statements are prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”). Use of Estimates The preparation of these financial statements requires our management to make estimates and assumptions about future events that affect the amounts reported in the financial statements and related notes. Future events and their effects cannot be determined with absolute certainty. Therefore, the determination of estimates requires the exercise of judgment. Comprehensive Loss Comprehensive income (loss) as defined includes all changes in equity during a period from non-owner sources. Items included in the Company’s comprehensive loss consist of unrealized gains (losses) on securities. Cash All highly liquid investments with a maturity date of three months or less at the date of purchase are considered to be cash equivalents. Revenue Recognition The restructured entity of True Nature Holding, Inc. which is focused on acquiring a series of businesses which specialize in compounding pharmacy activities, has recognized no revenues through December 31, 2016. In fiscal 2017, the Company will recognize revenues when all of the following criteria have been met: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred; (3) the selling price is fixed and determinable; and (4) collectability is reasonably assured. Stock-Based Compensation We recognize the compensation costs of share-based compensation arrangements based on the grant-date fair value and recognize the costs in the financial statements over the period during which employees are required to provide services. Share-based compensation cost for stock options is estimated at the grant date based on each option’s fair-value as calculated by the Black-Scholes-Merton (“BSM”) option-pricing model. Share-based compensation arrangements may include stock options, restricted share plans, performance based awards, share appreciation rights and employee share purchase plans. Such compensation amounts, if any, are amortized over the respective vesting periods of the option grant. Equity instruments issued to other than employees are recorded on the basis of the fair value of the instruments. In general, the measurement date is when either a (a) performance commitment, as defined, is reached or (b) the earlier of (i) the non-employee performance is complete or (ii) the instruments are vested. The measured value related to the instruments is recognized over a period based on the facts and circumstances of each particular grant. Convertible Instruments The Company reviews the terms of convertible debt and equity instruments to determine whether there are conversion features or embedded derivative instruments including embedded conversion options that are required to be bifurcated and accounted for separately as a derivative financial instrument. In circumstances where the convertible instrument contains more than one embedded derivative instrument, including conversion options that are required to be bifurcated, the bifurcated derivative instruments are accounted for as a single compound instrument. Also, in connection with the sale of convertible debt and equity instruments, the Company may issue free standing warrants that may, depending on their terms, be accounted for as derivative instrument liabilities, rather than as equity. When convertible debt or equity instruments contain embedded derivative instruments that are to be bifurcated and accounted for separately, the total proceeds allocated to the convertible host instruments are first allocated to the fair value of the bifurcated derivative instrument. The remaining proceeds, if any, are then allocated to the convertible instruments themselves, usually resulting in those instruments being recorded at a discount from their face amount. When the Company issues debt securities, which bear interest at rates that are lower than market rates, the Company recognizes a discount, which is offset against the carrying value of the debt. Such discount from the face value of the debt, together with the stated interest on the instrument, is amortized over the life of the instrument through periodic charges to income. In addition, certain conversion features are recognized as beneficial conversion features to the extent the conversion price as defined in the convertible note is less than the closing stock price on the issuance of the convertible notes. Common Stock Purchase Warrants The Company accounts for common stock purchase warrants in accordance with FASB ASC Topic 815, Accounting for Derivative Instruments and Hedging Activities (“ASC 815”). As is consistent with its handling of stock compensation and embedded derivative instruments, the Company’s cost for stock warrants is estimated at the grant date based on each warrant’s fair-value as calculated by the Black-Scholes-Merton (“BSM”) option-pricing model value method for valuing the impact of the expense associated with these warrants. Stockholders’ Equity Shares of common stock issued for other than cash have been assigned amounts equivalent to the fair value of the service or assets received in exchange. Common stock share and per share amounts in these financial statements have been adjusted for the effects of a 1 for 101 reverse stock split that occurred in January 2016. Per Share Data Basic loss per share is computed by dividing net loss by the weighted average number of common shares outstanding for the year. Diluted loss per share is computed by dividing net loss by the weighted average number of common shares outstanding plus common stock equivalents (if dilutive) related to warrants, options and convertible instruments. The Company has excluded all common equivalent shares outstanding for warrants, options and convertible instruments to purchase common stock from the calculation of diluted net loss per share because all such securities are antidilutive for the periods presented. As of December 31, 2016, the Company had no outstanding warrants or options. Income Taxes The Company accounts for income taxes under the asset and liability method which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the Company’s consolidated financial statements or tax returns. In estimating future tax consequences, the Company generally considers all expected future events other than possible enactments of changes in the tax laws or rates. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized. The Company has determined that a valuation allowance is needed due to recent taxable net operating losses, the sale of profitable divisions and the limited taxable income in the carry back periods. The effect on deferred tax assets and liabilities of a change in tax rates is recognized as income or expense in the period that includes the enactment date. Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes and certain tax loss carryforwards, less any valuation allowance. The Company accounts for uncertain tax positions as required in that a position taken or expected to be taken in a tax return is recognized in the consolidated financial statements when it is more likely than not (i.e., a likelihood of more than fifty percent) that the position would be sustained upon examination by tax authorities. A recognized tax position is then measured at the largest amount of benefit that is greater than fifty percent likely of being realized upon ultimate settlement. The Company does not have any material unrecognized tax benefits. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as components of interest expense and other expense, respectively, in arriving at pretax income or loss. The Company does not have any interest and penalties accrued. The Company is generally no longer subject to U.S. federal, state, and local income tax examinations for the years before 2012. Business Combinations The Company accounts for business combinations by recognizing the assets acquired, liabilities assumed, contractual contingencies, and contingent consideration at their fair values on the acquisition date. The purchase price allocation process requires management to make significant estimates and assumptions, especially with respect to intangible assets, estimated contingent consideration payments and pre-acquisition contingencies. Examples of critical estimates in valuing certain of the intangible assets we have acquired or may acquire in the future include but are not limited to: future expected cash flows from product sales, support agreements, consulting contracts, other customer contracts, and acquired developed technologies and patents; and discount rates utilized in valuation estimates. Unanticipated events and circumstances may occur that may affect the accuracy or validity of such assumptions, estimates or actual results. Additionally, any change in the fair value of the acquisition-related contingent consideration subsequent to the acquisition date, including changes from events after the acquisition date, such as changes in our estimates of relevant revenue or other targets, will be recognized in earnings in the period of the estimated fair value change. A change in fair value of the acquisition-related contingent consideration or the occurrence of events that cause results to differ from our estimates or assumptions could have a material effect on the consolidated financial position, statements of operations or cash flows in the period of the change in the estimate. Impairment of Long-Lived Assets Long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated future cash flows, an impairment charge is recognized in the amount by which the carrying amount of the asset exceeds the fair value of the asset. Assets to be disposed would be separately presented in the consolidated balance sheet and reported at the lower of the carrying amount or fair value less costs to sell, and are no longer depreciated. The assets and liabilities of a disposal group classified as held-for-sale would be presented separately in the appropriate asset and liability sections of the consolidated balance sheet, if material. No impairment losses have been realized for the periods presented. Financial Instruments and Fair Values The fair value of a financial instrument represents the amount at which the instrument could be exchanged in a current transaction between willing parties, other than in a forced or liquidation sale. Fair value estimates are made at a specific point in time, based upon relevant market information about the financial instrument. In determining fair value, we use various valuation methodologies and prioritize the use of observable inputs. We assess the inputs used to measure fair value using a three-tier hierarchy based on the extent to which inputs used in measuring fair value are observable in the market: Level 1 – inputs include exchange quoted prices for identical instruments and are the most observable. Level 2 – inputs include brokered and/or quoted prices for similar assets and observable inputs such as interest rates. Level 3 – inputs include data not observable in the market and reflect management judgment about the assumptions market participants would use in pricing the asset or liability. The use of observable and unobservable inputs and their significant in measuring fair value are reflected in our hierarchy assessment. The carrying amount of cash, prepaid assets, accounts payable and accrued liabilities approximates fair value due to the short-term maturities of these instruments. Because cash and cash equivalents are readily liquidated, management classifies these values as Level 1. The fair value of the debentures, approximate their book value as the instruments are short-term in nature and contain market rates of interest. Because there is no ready market or observable transactions, management classifies the debentures as Level 3. Recently Issued Accounting Standards In April 2015, the FASB issued ASU 2015-03, Simplifying the Presentation of Debt Issuance Costs, which relates to the financial statement presentation of debt issuance costs. This guidance requires debt issuance costs to be presented in the balance sheet as a reduction of the related debt liability rather than an asset. The guidance is effective for annual and interim periods beginning after December 15, 2015 and early adoption is permitted and will only result in a change in presentation of the costs on the balance sheet. In November 2015, the FASB issued ASU 2015-17, Balance Sheet Classification of Deferred Taxes. The guidance requires that all deferred tax assets and liabilities, along with any related valuation allowance, be classified as noncurrent on the balance sheet. The guidance becomes effective for annual reporting periods beginning after December 15, 2016 with early adoption permitted. The adoption of this guidance will only result in a change in the presentation of deferred taxes on the balance sheet.

Note 3 - Newco4pharmacy Transac

Note 3 - Newco4pharmacy Transaction	12 Months Ended
	Dec. 31, 2016
Notes
Note 3 - Newco4pharmacy Transaction	Note 3 – Newco4pharmacy Transaction On December 9, 2015, Trunity Holdings, Inc. acquired 100% of the membership interests of Newco4pharmacy, LLC. The consideration paid was the issuance of a newly created Series X Preferred stock which was exchanged on December 31, 2015 for 10,000,000 shares of the Company’s common stock. The $106,900 fair value of the preferred stock issued and common stock exchanged approximated the fair value of the assets acquired from Newco4pharmacy, LLC which consisted of cash. Acquisition costs were nominal pertaining to the transaction. On December 31, 2015, the Company completed the restructuring and spin-out of software educational business, resulting in True Nature Holding, Inc. becoming purely focused on acquiring a series of businesses which specialize in compounding pharmacy activities, largely direct to consumers, doctors and veterinary professionals. The results of the operations associated with the Spin-Out company and Trunity Holdings, Inc., qualifies as discontinued operations. The results of operations associated with discontinued operations were as follows: For the Year ending December 31, 2015 Net Sales $ 464,786 Cost of sales 220,228 Gross Profit 244,558 Operating Expenses: Research and development 734,985 Selling, general and administrative 938,799 Total operating expenses 1,673,784 Operating Loss from Discontinued Operations (1,429,226) Other Expense: Interest expense, net (775,564) Disposal on fixed assets — Gain (Loss) on debt extinguishment 1,867,428 Net Loss from Discontinued Operations $ (337,362) Other Comprehensive Gain Net of Tax: Foreign currency translation adjustments 24,815 Comprehensive Loss from Discontinued Operations $ (312,547)

Note 4 -deconsolidation of Acqu

Note 4 -deconsolidation of Acquisition	12 Months Ended
	Dec. 31, 2016
Notes
Note 4 -deconsolidation of Acquisition	Note 4 –Deconsolidation of acquisition On April 29, 2016, subject to approval by the Georgia Board of Pharmacy, the Company entered into definitive documents to acquire P3 Compounding of Georgia, LLC, (“ P3 The fair value of the consideration paid pertaining to the acquisition of P3 was $1,618,200. Consideration for the transaction was structured as follows: The Company issued 340,000 shares of common stock with a fair value of $1,183,200 based on the closing price of the True Nature’s common stock on April 29, 2016. In addition, Mr. Casey Gaetano, a former owner of P3, received an employment contract with True Nature for 3 years as VP of Corporate Development, at an annual salary of $125,000, plus normal benefits commensurate with other executives in the Company of equal stature. He also received on April 29, 2016, 125,000 shares of restricted at a value of $3.48 per share in exchange for becoming the Company’s VP of Corporate Development. No cash consideration was paid under this agreement, and it was fully cancelled without further obligation as a part of the deconsolidation transaction. The shares were valued at $435,000 and will remain the property of Mr. Gaetano. As the company never attained full control of P3, the business was deconsolidated from the company’s financials as of September 30, 2016. Loss on Deconsolidation As the Company did not obtain effective control of the P3 business, the Company deconsolidated the business effective September 30, 2016 in accordance with ASC 810 and the disclosures herein were also made in accordance with ASC 810. As a result, the Company recorded a loss from deconsolidation of $1,618,200, based on the fair value of shares issued of $1,618,200; the loss from deconsolidation is included within selling, general and administrative expenses.

Note 5 - Related Party Transact

Note 5 - Related Party Transactions	12 Months Ended
	Dec. 31, 2016
Notes
Note 5 - Related Party Transactions	Note 5 – Related Party Transactions On January 25, 2016 two board members were each awarded 100,000 of shares of the Company in exchange for their services as board members. The shares were valued at $145,000 based on the closing market price on the date of grant. On April 25, 2016 a board member was awarded 100,0000 shares of the Company in exchange for his services on the board and 1,000,000 non-qualified stock options for his position as CEO. The stock options were subsequently cancelled in conjunction with his resignation on September 23, 2016, and 100,000 shares of restricted common stock valued at $47,680, based on the closing market price on the date of grant, in conjunction with the cancellation of all amounts owed as of the date of his resignation. On May 25, 2016, a board member was awarded 100,000 shares, valued at $235,000, based on the closing market price on the date of grant, from the Company in exchange for his services on the board. On September 23, 2016, the Company appointed three (3) new directors to the Board of Directors, and each received 100,000 shares, each valued at $27,990, based on the closing market price on the date of grant, of restricted common stock in conjunction with their appointment. On September 27, 2016, the Company accepted the resignations of its former Chairman & CFO, and former CEO. The former CFO had a consulting agreement in the amount of $10,000 per month for professional fees. The Company’s former CEO had an employment agreement effective June 7, 2016 that would have paid him a monthly salary in the amount of $12,500 per month for remainder of 2016, $17,500 per month for the calendar year of 2017, $22,500 per month for the calendar year of 2018 and $25,000 per month for the calendar year of 2019. No payments have been made to the former CEO. Both of these agreements were fully cancelled and the Company has no further obligation to either going forward. Further, the former CFO has agreed to return for cancellation 2,000,000 of his shares of restricted common stock, and to use 100,000 shares to settle an obligation to a former employee. The former CEO had been awarded options for the purchase of 1,000,000 shares of restricted common stock, which were all cancelled in conjunction with his resignation. In addition, a shareholder of the Company had a consulting agreement in the amount of $10,000 per month for professional fees. The shareholder and the Company have agreed to terminate their agreement with the Company as of September 30, 2016. In consideration of all amounts owed, the Company has issued 966,666, valued at $290,000 based on the closing market price on the date of grant, restricted common stock, and the consultant has cancelled $290,000 in amounts owed. The amounts owed consist of a) $80,000 in advances to the Company, or obligations paid to the Company, b) $120,000 in consulting fees owed and c) reimbursement of $90,000 of costs related to the formation of Newco4pharmacy, LLC, which was acquired by the Company in December 2015. On December 30, 2016, the Board of Directors of the Company issued 100,000 shares of restricted common stock to a consultant, who subsequently became the CEO and CFO of the Company as compensation for his contribution during the prior 90 days. This charge to earnings for this issuance was $19,080; On December 30, 2016, the Board voted to issue to the existing Board of Directors members 100,000 shares each of restricted common stock as additional compensation for services during the prior 90 days. Each of the recipients abstained from the vote on their issuance so as not to be voting on their own issuance, and did vote for the issuance to their fellow Board members. The charge to earnings for this issuance was $19,080, for each of the three (3) directors, or a total of $57,240. The Company had accounts payable from related party transactions of $106,866 as of December 31, 2016. The balance was made up of the following: a) two members of the Board of Directors were due $12,000 each for compensation expense that had not been paid; b) the former CEO and CFO of the Company were owed for reimbursable expenses that totaled $75,866; and c) a shareholder had paid for expenses of the Company directly to several vendors for a total of $7,000.

Note 6 - Debt

Note 6 - Debt	12 Months Ended
	Dec. 31, 2016
Notes
Note 6 - Debt	Note 6 – Debt On March 18, 2016, the Company issued a 12% Convertible Promissory Note (the “Convertible Note A”) in the principal amount of $60,000 to the Lender. Pursuant to the terms of the Convertible Note, on the date thereof, the Company issued the Convertible Note to the Lender and, as consideration therefor, the Lender paid the Company in cash the full principal amount of the Convertible Note. Upon issuance, the lender was awarded 15,000 restricted common shares as an origination fee which will have piggy back registration rights. On September 19, 2016, the Company issued the lender an additional 15,000 restricted common shares at a price of $0.30 per share to extend the term of the loan agreement. The cost to the Company was $4,050 in Interest Expense. This note is currently in default. Accrued interest at December 31, 2016, was $3,660. Pursuant to the terms of the Convertible Note A, the Company is obligated to pay monthly installments of not less than $1,000 the first of each month commencing the month following the execution of this note until its full maturity on September 16, 2016 at which time the Company is obligated to repay the full principal amount of the Convertible Note A. The Convertible Note A is convertible by the holder at any time into shares of the Company’s common stock at an effective conversion price of $1.00 and throughout the duration of this Convertible Note the holder has the right to participate in any and other financing the Company may engage in with the same terms and option as all other investors. The Company allocated the face value of the Convertible Note A to the shares and the note based on relative fair values, and the amount allocated to the shares of $18,750 was recorded as a discount against the note. The beneficial conversion feature of $9,375 was recorded as a debt discount with an offsetting entry to additional paid-in capital decreasing the note payable and increasing debt discount. The debt discount is being amortized to interest expense over the term of the debt. For the year ended December 31, 2016, debt discount amortization related to the Convertible Note A was $28,125. On May 19, 2016, the Company issued a 10% Convertible Promissory Note (the “Convertible Note B”) in the principal amount of $100,000 to the Lender. Pursuant to the terms of the Convertible Note B, on the date thereof, the Company issued the Convertible Note B to the Lender and, as consideration therefor, the Lender paid the Company in cash the full principal amount of the Convertible Note B. Upon issuance the lender was awarded 66,666 warrants to purchase common stock of the Company at an exercise price of $2.50 for a term of twenty-four month. The warrants were valued at $103,086 with $100,000 as a debt discount; the additional $3,086 was expensed as additional interest expense. The debt discount was fully amortized during the year ended December 31, 2016. This obligation, including all warrants, penalties and interest due was cancelled as of September 30, 2016 in consideration of the issuance of 400,000 shares of restricted common stock valued at $120,000. At the time of conversion, the note about was $100,000 and total accrued interest was $3,671. Therefore, as a result of the conversion, a loss of $16,329 recognized in the year ended December 31, 2016. August 2014 Convertible Debentures (Series C) As part of the restructuring all debentures issued by Trunity Holdings, Inc., to fund the former educational business were eligible to participate in a debt conversion however one debenture holder that was issued a Series C Convertible Debenture (the “Series C Debenture”) in August 2014 with an aggregate face value of $100,000 in exchange for the cancellation of Series B Convertible Debentures with a carrying value of $110,833 did not convert. The Series C Debenture accrues interest at an annual rate of 10%, matured November 2015, and is convertible into our common stock at a conversion rate of $20.20 per share. The holders of the Series C Debenture also received warrants to acquire 4,950 shares post-split of common stock for an exercise price of $20.20 per share, exercisable over five years. The former educational business allocated the face value of the Series C Debenture to the warrants and the debentures based on its relative fair values, and allocated to the warrants, which was recorded as a discount against the Series C Debenture, with an offsetting entry to additional paid-in capital. The discount was fully expensed upon execution of the new debentures as debt extinguishment costs within discontinued operations. As of December 31, 2016, the carrying value of this Series C Debenture was $110,833 and accrued interest expense of $24,420. This note is currently in default. November 2014 Convertible Debentures (Series D) As part of the restructuring all debentures issued by Trunity Holdings, Inc., to fund the former educational business were eligible to participate in a debt conversion however one debenture holder that was issued a Series D Convertible Debenture (the “Series D Debenture”) in November 2014 with an aggregate face value of $10,000 in exchange for the cancellation of Series B Convertible Debenture with a carrying value of $11,333 that did not participate in the debt conversion restructuring. The Series D Debenture accrues interest at an annual rate of 12%, matured November 2015, and is convertible into our common stock at a conversion rate of $16.67 per share. The holders of the Series D Debenture also received warrants to acquire 495 shares post-split of common stock for an exercise price of $20.20 per share, exercisable over five years. The former educational business allocated the face value of the Series D Debenture to the warrants and the debentures based on their relative fair values, and allocated to the warrants, which was recorded as a discount against the Series D Debenture, with an offsetting entry to additional paid-in capital. The discount was fully expensed upon execution of the new debentures as debt extinguishment costs within discontinued operations. As of December 31, 2016, the carrying value of the Series D Debenture was $11,333 and accrued interest expense of $2,941. This note is currently in default. Short term loan As a result of the acquisition of P3 Compounding of Georgia, LLC the Company had a short-term convertible note with a loan agency for a principal amount of $52,000 for the purchase of future sales and credit card receivables of P3. Under the terms of the receivable purchase agreement, the Company purchased an advance of $50,000 plus $2,000 for origination costs with a 10.5% daily interest rate to be repaid over 160 days at a repayment amount of $451.75 per day. Upon maturity, the loan the total repayment amount will be $72,280. As of the fiscal year ending December 31, 2016 the carrying value of this short-term loan was $26,925. For year ending December 31, 2016, no interest expense related to this loan was recorded in the Company’s consolidated financial statements as the effective date of acquisition was the last day of the quarter. The origination fee and interest were recorded as debt discount on the date of issuance in the amount of $22,280 and $22,280 was amortized during the year ending December 31, 2016. The note is currently in default. On July 11, 2016, the Company entered into a short-term loan with a loan agency for the principal amount of $48,000. Under the terms of the loan, the Company will make daily payments of $434.38 for a term of 160 for a total repayment amount of $69,500. As of December 31, 2016, the carrying value of this loan was $45,175. The origination fee and interest were recorded as debt discount on the date of issuance in the amount of $21,500 and $21,500 was amortized during the year ending December 31, 2016. This note is currently in default. The convertible notes are convertible into common shares as of October 3, 2016 due to the default provision which allows conversion after default into 85% of the average trading price in the prior five days. The beneficial conversion features of $25,146 and $32,541 for the May and July notes, respectively, were recorded as a debt discount with an offsetting entry to additional paid-in capital decreasing the note payable and increasing debt discount. The debt discounts were both fully amortized during the year ended December 31, 2016. The convertible notes also included common stock payable amounts of $10,000 each, which were recorded as a debt discount and an increase to common stock payable. These two debt discounts were also fully amortized during the year ended December 31, 2016.

Note 7 - Stockholders' Deficit

Note 7 - Stockholders' Deficit	12 Months Ended
	Dec. 31, 2016
Notes
Note 7 - Stockholders' Deficit	Note 7 – Stockholders’ Deficit Sale of Common Stock Shares for Stock Based Compensation Shares issued for convertible note payable issuance Shares issued for conversion of accounts payable Shares issued for conversion of debt Debt beneficial conversion feature for convertible note payable Stock payable for debt

Note 8 - Stock Options

Note 8 - Stock Options	12 Months Ended
	Dec. 31, 2016
Notes
Note 8 - Stock Options	Note 8 – Stock Options The Company had two Employee, Director and Consultant Stock Option Plans that were not terminated as a result of the fiscal 2015 restructuring of the Company and spin-out and have continued as part of the operations as detailed below. In fiscal 2015, the option pool pertaining to the 2009 Employee, Director and Consultant Stock Option Plan (the “2009 Plan”) was adjusted for a 1 for 101 stock split due to the spin-out and restructuring plan, resulting in an authorized option pool of 18,152. Stock options typically vest over a three-year period and have a life of ten years from the date granted. As of December 31, 2016, there were 3,610 shares available for future awards under this plan. In fiscal 2015, the option pool pertaining to the 2012 Employee, Director and Consultant Stock Option Plan (the “2012 Plan”) was adjusted for a 1 for 101 stock split due to the spin-out and restructuring plan, resulting in an authorized options pool of 74,257. Stock options typically vest over a three-year period and have a life of ten years from the date granted. As of December 31, 2016, there were 45,673 shares available for future awards under this plan. In addition, there are approximately 24,753 in options outstanding that were issued to a former CEO of spin-out Company in fiscal 2014. These options issued are outside of the 2009 and 2012 Plans. On June 1, 2016 Jim Driscoll was granted for his position as Chief Executive Officer (CEO) of the Company options to purchase up to 1,000,000 shares of Common Stock outside of the Company’s 2009 and 2012 stock option plans (the “Option Agreement”). These options covered 250,000 shares at an exercise price of $1.00 per share to be granted immediately and three additional tranches of 250,000 shares each at an exercise price of $1.50, $2.00 and $2.50 per share, respectively. The remaining three tranches will vest equally over the next three years with the first fully vesting on May 31, 2017 through May 31, 2019. The term of the options will be for a period of five years and may be exercised at any time as to the vested shares. These options were fully cancelled in conjunction with his resignation as of September 27, 2016. During the fiscal year ended December 31, 2016, the Company recorded stock compensation expense related to the options granted to Mr. Driscoll of $314,680. The grant-date fair value of options was estimated using the Black-Scholes option pricing model. The per share weighted average fair value of stock options granted for Mr. Driscoll was a range of $1.35-$1.76 and was determined using the following assumptions: expected price volatility is 80.39%, risk-free interest rate of 1.39%, zero expected dividend yield, and 4.0 years expected life of options. The expected term of options granted is based on the simplified method in accordance with Securities and Exchange Commission Staff Accounting Bulletin 107, and represents the period of time that options granted are expected to be outstanding. The Company makes assumptions with respect to expected stock price volatility based on the average historical volatility of peers with similar attributes. In addition, the Company determines the risk free rate by selecting the U.S. Treasury with maturities similar to the expected terms of grants, quoted on an investment basis in effect at the time of grant for that business day. As a result of the cancellation of these warrants, the Company has recovered $314,680 as resulted of the elimination of this reserve. As of December 31, 2016, unrecognized stock compensation expense related to unvested stock options under all Plans was $0. Total stock compensation expense recorded to selling, general and administrative expenses on the consolidated statements of operations and comprehensive for the fiscal year ended December 31, 2016 related to the all Plans and options that vested during the period was $0. A summary of options issued, exercised and cancelled are as follows: Shares Weighted- Average Exercise Price ($) Weighted- Average Remaining Contractual Term Aggregate Intrinsic Value ($) Outstanding at December 31, 2015 67,879 $ 21.40 7.17 — Granted 1,000,000 1.75 5.00 — Cancelled (1,000,000) 1.75 5.00 — Outstanding at December 31, 2016 67,879 $ 21.40 6.42 — Exercisable at December 31, 2016 67,879 $ 21.40 6.42 —

Note 9- Stock Warrants

Note 9- Stock Warrants	12 Months Ended
	Dec. 31, 2016
Notes
Note 9- Stock Warrants	Note 9– Stock Warrants Subsequent to the restructuring of the Company and the spin-out, the Company had warrants to purchase common stock outstanding that were not terminated and have continued as part of the operations as detailed below. The warrants were adjusted for a 1 for 101 stock split due to the spin-out and restructuring plan as authorized. All warrants outstanding as of December 31, 2016 are scheduled to expire at various dates through 2019. A summary of warrants issued, exercised and expired are as follows: Shares Weighted- Average Exercise Price ($) Weighted- Average Remaining Contractual Term Outstanding at December 31, 2015 78,462 $ 29.55 3.43 Granted 66,666 2.50 2.00 Expired (2,475) 50.50 - Outstanding at December 31, 2016 142,653 $ 17.42 2.50 Exercisable at December 31, 2016 142,653 $ 17.42 2.50

Note 10 - Income Taxes

Note 10 - Income Taxes	12 Months Ended
	Dec. 31, 2016
Notes
Note 10 - Income Taxes	Note 10 – Income Taxes The Company accounts for income taxes under standards issued by the FASB. Under those standards, deferred tax assets and liabilities are recognized for future tax benefits or consequences attributable to temporary differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. A valuation allowance is provided for significant deferred tax assets when it is more likely than not that such assets will not be realized through future operations. No provision for federal income taxes has been recorded due to the available net operating loss carry forwards of approximately $1,351,095 will expire in various years through 2033. Future tax benefits which may arise as a result of these losses have not been recognized in these financial statements, as their realization is determined not likely to occur and accordingly, the Company has recorded a valuation allowance for the future tax loss carry forwards. The actual income tax provisions differ from the expected amounts calculated by applying the statutory income tax rate to the Company's loss before income taxes. The components of these differences are as follows at December 31, 2016 and December 31, 2015: 2016 2015 Net tax loss carry-forwards $ 1,351,095 $ 03,893 Statutory rate 34% 34% Expected tax recovery 459,372 103,324 Change in valuation allowance (459,372) (103,324) Income tax provision $ - $ - Components of deferred tax asset: Non capital tax loss carry forwards $ 459,372 $ 103,324 Less: valuation allowance (459,372) (103,324) Net deferred tax asset $ - $ -

Note 11 - Commitments and Conti

Note 11 - Commitments and Contingencies	12 Months Ended
	Dec. 31, 2016
Notes
Note 11 - Commitments and Contingencies	Note 11 – Commitments and Contingencies Legal National Council for Science and the Environment, Inc. v. Trunity Holdings, Inc., Case No. 2015 CA 009726 B, Superior Court for the District of Columbia, Civil Division. This action was filed on December 16, 2015 by the National Council for Science and the Environment, Inc. (“NCSE”) in the state court in the District of Columbia against Trunity Holdings, Inc. (“Trunity”) and alleges claims for Breach of Contract. Acknowledgement of Indebtedness and Settlement Agreement and Quantum Meruit arising out of an agreement entered into between NCSE and Trunity in 2014. The Complaint seeks damages in the amount of $177,270, inclusive of attorney’s fees, costs and accrued interest, continuing interest in the amount of 12% per annum and attorney’s fees and costs of collection relating to the case. The Company in its answer on January 27, 2016, denied the material allegations made by NCSE, asserted a number of affirmative defenses and filed a counterclaim alleging claims for fraud, negligent misrepresentation, breach of fiduciary duty, breach of contract and unjust enrichment. In its counterclaim, the Company will seek actual and compensatory damages against NCSE that it believes exceed the amount sought by NCSE on its claims, pre-judgment interest, punitive damages and all costs and expenses, including attorney’s fees, incurred by the Company in bringing its claims against NCSE. On September 23, 2016 the Company settled this obligation with an agreement to pay $48,500 to NCSE if paid by November 4, 2016, and $75,000 if paid later. The Company has not paid the amounts as of the date of this filing, and has recorded the obligation at $75,000. This amount, plus any related costs, including legal fees, shall be reimbursed by the spin-out company, Trunity, Inc., a Florida company. On July 6, 2016, the Company appointed Gary Meyer to the newly created position of Chief Compliance Officer. Mr Meyer was terminated as of September 23, 2016. After being terminated, Mr. Meyer threatened to take legal action against the Company for breach of an alleged employment agreement. The Company took a reserve of $280,000 at September 30, 2016 in consideration of any potential claims that might be brought by Mr. Meyer. On December 31, 2016, Mr. Meyer and the Company entered into a Settlement Agreement and Release under which Mr. Meyer fully releases and indemnifies the Company against any claims he might have in consideration of the issuance of 150,000 shares of restricted shares of the Company's common stock, at a recorded cost of $28,620.

Note 12 - Financial Condition a

Note 12 - Financial Condition and Going Concern	12 Months Ended
	Dec. 31, 2016
Notes
Note 12 - Financial Condition and Going Concern	Note 12 – Financial Condition and Going Concern As of December 31, 2016, the Company had cash on hand of $0 and liabilities of $1,067,874 and has incurred a loss from operations. True Nature Holding’s planned principal operations pertain to the business development and acquisition of pharmaceutical compounding companies. The Company’s activities are subject to significant risks and uncertainties, including failing to secure additional funding to execute its business plan. These factors raise substantial doubt about the Company’s ability to continue as a going concern. The Company’s continuance is dependent on raising capital and generating revenues sufficient to sustain operations. The Company believes that the necessary capital will be raised and has entered into discussions to do so with certain individuals and companies. However, as of the date of these consolidated financial statements, no formal agreement exists. The accompanying consolidated financial statements do not include any adjustments that might be necessary should the Company be unable to secure the necessary capital and continue as a going concern.

Note 13 - Subsequent Events

Note 13 - Subsequent Events	12 Months Ended
	Dec. 31, 2016
Notes
Note 13 - Subsequent Events	Note 13 – Subsequent Events We began 2016 with five (5) directors and a single member of the management team. By the First Quarter of 2017, the Company had in place four (4) directors and three members of the management team. We believe that True Nature’s management team can remain small in the near term, and will consist of a four-person management team with experience in 1) public company accounting and finance, 2) multi-unit supply chain management including retail and wholesale operations, 3) brand marketing aimed at consumer through online and traditional retail channels, and 4) public equity finance. We believe our current team addresses most of these areas, and we anticipate further additions as our size, and funding, can allow. Biographical and other information on our executive officers and directors is set forth in “Item 10: Directors, Executive Officers, and Corporate Governance” of this Report. On January 25, 2017, the Board of Director appointed Christopher Knauf, age 44, as the Chief Executive Officer and Chief Financial Officer of the Company. From 2014 to present, Mr. Knauf served as a consultant for small to mid-size emerging growth companies, both public and private. From 2012 to 2014, he served as CEO/CFO of Built NY, Inc, a consumer products company based in New York, NY. Prior to that, from 2004 to 2012, Mr. Knauf was Head of Finance and Operations for the Consumer Products division of A+E Networks, Inc, a provider of television content worldwide. From 2002 to 2004, He was the CFO of Intermix, Inc, a New York, NY based apparel retailer. His education includes an MBA, Finance concentration, 1999, Fordham University, New York, NY. BS, Finance, 1995, Fairfield University, Fairfield, CT On February 7, 2017 Mr. James Czirr joined the Board of Directors. Mr. Czirr, age 62, is most recently involved with Galectin Therapeutics, Inc. (NASDAQ:GALT), both personally and as an investment his funds. He served as Chairman of the Board for Galectin from February 2009, and Executive Chairman from February 2010 until January 2016. He now sits on the Board as the representative for their Series B Preferred holders. He is a co-founder of 10X Fund, L.P. and is a managing member of 10X Capital Management LLC, the general partner of 10X Fund, L.P. Mr. Czirr was a co-founder of Galectin Therapeutics in July 2000. Mr. Czirr was instrumental in the early stage development of Safe Science Inc., a developer of anti-cancer drugs; served from 2005 to 2008 as Chief Executive Officer of Minerva Biotechnologies Corporation, a developer of nano particle bio chips to determine the cause of solid tumors; and was a consultant to Metalline Mining Company Inc., now known as Silver Bull Resources, Inc., (AMEX: SVBL), a mineral exploration company seeking to become a low-cost producer of zinc. Mr. Czirr received a B.B.A. degree from the University of Michigan. On February 14, 2017, the Board of Director appointed Louis Deluca as the Chief Operating Officer of True Nature Holdings, Inc. Mr. Deluca, age 58, served as VP of Operations for Mondetta US, Inc. an online apparel designer and retailer, from 2015 to 2016. From 2012-2015, he served as the COO of The Ivory Company, a multichannel home décor retailer based in Atlanta, GA. From 2007 to present, Mr Deluca was the Founder and CEO of Marietta Sign Company, a manufacturer and designer of customer signage based in Atlanta, GA. From 1981 to 2007, he served as Director of Inventory Planning and Sourcing at The Home Depot. He received a Technical Drafting Certificate from Gwinnett Technical College in 1977 and studied Business Management at the University of Phoenix. On February 14, 2017, the Board of Director engaged Susanne Leahy as an Advisor, subject to certain conditions, and as an advisor to assist with financial reporting and accounting in the interim. Ms. Leahy, age 47, served as the SVP of Finance and Operations for Cinedigm (NASDAQ: CIDM) from 2012-2016. From 2000-2012, she served as VP of Finance and Operations for New Video group, a home entertainment distributor company based in New York NY. Ms. Leahy received a BS in Accounting from New York Institute of Technology in 1995.

Note 2 - Summary of Significa20

Note 2 - Summary of Significant Accounting Policies: Basis of Accounting (Policies)	12 Months Ended
	Dec. 31, 2016
Policies
Basis of Accounting	Basis of Accounting The consolidated financial statements are prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”).

Note 2 - Summary of Significa21

Note 2 - Summary of Significant Accounting Policies: Use of Estimates (Policies)	12 Months Ended
	Dec. 31, 2016
Policies
Use of Estimates	Use of Estimates The preparation of these financial statements requires our management to make estimates and assumptions about future events that affect the amounts reported in the financial statements and related notes. Future events and their effects cannot be determined with absolute certainty. Therefore, the determination of estimates requires the exercise of judgment.

Note 2 - Summary of Significa22

Note 2 - Summary of Significant Accounting Policies: Comprehensive Loss (Policies)	12 Months Ended
	Dec. 31, 2016
Policies
Comprehensive Loss	Comprehensive Loss Comprehensive income (loss) as defined includes all changes in equity during a period from non-owner sources. Items included in the Company’s comprehensive loss consist of unrealized gains (losses) on securities.

Note 2 - Summary of Significa23

Note 2 - Summary of Significant Accounting Policies: Cash (Policies)	12 Months Ended
	Dec. 31, 2016
Policies
Cash	Cash All highly liquid investments with a maturity date of three months or less at the date of purchase are considered to be cash equivalents.

Note 2 - Summary of Significa24

Note 2 - Summary of Significant Accounting Policies: Revenue Recognition (Policies)	12 Months Ended
	Dec. 31, 2016
Policies
Revenue Recognition	Revenue Recognition The restructured entity of True Nature Holding, Inc. which is focused on acquiring a series of businesses which specialize in compounding pharmacy activities, has recognized no revenues through December 31, 2016. In fiscal 2017, the Company will recognize revenues when all of the following criteria have been met: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred; (3) the selling price is fixed and determinable; and (4) collectability is reasonably assured.

Note 2 - Summary of Significa25

Note 2 - Summary of Significant Accounting Policies: Stock-based Compensation (Policies)	12 Months Ended
	Dec. 31, 2016
Policies
Stock-based Compensation	Stock-Based Compensation We recognize the compensation costs of share-based compensation arrangements based on the grant-date fair value and recognize the costs in the financial statements over the period during which employees are required to provide services. Share-based compensation cost for stock options is estimated at the grant date based on each option’s fair-value as calculated by the Black-Scholes-Merton (“BSM”) option-pricing model. Share-based compensation arrangements may include stock options, restricted share plans, performance based awards, share appreciation rights and employee share purchase plans. Such compensation amounts, if any, are amortized over the respective vesting periods of the option grant. Equity instruments issued to other than employees are recorded on the basis of the fair value of the instruments. In general, the measurement date is when either a (a) performance commitment, as defined, is reached or (b) the earlier of (i) the non-employee performance is complete or (ii) the instruments are vested. The measured value related to the instruments is recognized over a period based on the facts and circumstances of each particular grant.

Note 2 - Summary of Significa26

Note 2 - Summary of Significant Accounting Policies: Convertible Instruments (Policies)	12 Months Ended
	Dec. 31, 2016
Policies
Convertible Instruments	Convertible Instruments The Company reviews the terms of convertible debt and equity instruments to determine whether there are conversion features or embedded derivative instruments including embedded conversion options that are required to be bifurcated and accounted for separately as a derivative financial instrument. In circumstances where the convertible instrument contains more than one embedded derivative instrument, including conversion options that are required to be bifurcated, the bifurcated derivative instruments are accounted for as a single compound instrument. Also, in connection with the sale of convertible debt and equity instruments, the Company may issue free standing warrants that may, depending on their terms, be accounted for as derivative instrument liabilities, rather than as equity. When convertible debt or equity instruments contain embedded derivative instruments that are to be bifurcated and accounted for separately, the total proceeds allocated to the convertible host instruments are first allocated to the fair value of the bifurcated derivative instrument. The remaining proceeds, if any, are then allocated to the convertible instruments themselves, usually resulting in those instruments being recorded at a discount from their face amount. When the Company issues debt securities, which bear interest at rates that are lower than market rates, the Company recognizes a discount, which is offset against the carrying value of the debt. Such discount from the face value of the debt, together with the stated interest on the instrument, is amortized over the life of the instrument through periodic charges to income. In addition, certain conversion features are recognized as beneficial conversion features to the extent the conversion price as defined in the convertible note is less than the closing stock price on the issuance of the convertible notes.

Note 2 - Summary of Significa27

Note 2 - Summary of Significant Accounting Policies: Common Stock Purchase Warrants (Policies)	12 Months Ended
	Dec. 31, 2016
Policies
Common Stock Purchase Warrants	Common Stock Purchase Warrants The Company accounts for common stock purchase warrants in accordance with FASB ASC Topic 815, Accounting for Derivative Instruments and Hedging Activities (“ASC 815”). As is consistent with its handling of stock compensation and embedded derivative instruments, the Company’s cost for stock warrants is estimated at the grant date based on each warrant’s fair-value as calculated by the Black-Scholes-Merton (“BSM”) option-pricing model value method for valuing the impact of the expense associated with these warrants.

Note 2 - Summary of Significa28

Note 2 - Summary of Significant Accounting Policies: Stockholders' Equity (Policies)	12 Months Ended
	Dec. 31, 2016
Policies
Stockholders' Equity	Stockholders’ Equity Shares of common stock issued for other than cash have been assigned amounts equivalent to the fair value of the service or assets received in exchange. Common stock share and per share amounts in these financial statements have been adjusted for the effects of a 1 for 101 reverse stock split that occurred in January 2016.

Note 2 - Summary of Significa29

Note 2 - Summary of Significant Accounting Policies: Per Share Data (Policies)	12 Months Ended
	Dec. 31, 2016
Policies
Per Share Data	Per Share Data Basic loss per share is computed by dividing net loss by the weighted average number of common shares outstanding for the year. Diluted loss per share is computed by dividing net loss by the weighted average number of common shares outstanding plus common stock equivalents (if dilutive) related to warrants, options and convertible instruments. The Company has excluded all common equivalent shares outstanding for warrants, options and convertible instruments to purchase common stock from the calculation of diluted net loss per share because all such securities are antidilutive for the periods presented. As of December 31, 2016, the Company had no outstanding warrants or options.

Note 2 - Summary of Significa30

Note 2 - Summary of Significant Accounting Policies: Income Taxes (Policies)	12 Months Ended
	Dec. 31, 2016
Policies
Income Taxes	Income Taxes The Company accounts for income taxes under the asset and liability method which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the Company’s consolidated financial statements or tax returns. In estimating future tax consequences, the Company generally considers all expected future events other than possible enactments of changes in the tax laws or rates. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized. The Company has determined that a valuation allowance is needed due to recent taxable net operating losses, the sale of profitable divisions and the limited taxable income in the carry back periods. The effect on deferred tax assets and liabilities of a change in tax rates is recognized as income or expense in the period that includes the enactment date. Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes and certain tax loss carryforwards, less any valuation allowance. The Company accounts for uncertain tax positions as required in that a position taken or expected to be taken in a tax return is recognized in the consolidated financial statements when it is more likely than not (i.e., a likelihood of more than fifty percent) that the position would be sustained upon examination by tax authorities. A recognized tax position is then measured at the largest amount of benefit that is greater than fifty percent likely of being realized upon ultimate settlement. The Company does not have any material unrecognized tax benefits. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as components of interest expense and other expense, respectively, in arriving at pretax income or loss. The Company does not have any interest and penalties accrued. The Company is generally no longer subject to U.S. federal, state, and local income tax examinations for the years before 2012.

Note 2 - Summary of Significa31

Note 2 - Summary of Significant Accounting Policies: Business Combinations (Policies)	12 Months Ended
	Dec. 31, 2016
Policies
Business Combinations	Business Combinations The Company accounts for business combinations by recognizing the assets acquired, liabilities assumed, contractual contingencies, and contingent consideration at their fair values on the acquisition date. The purchase price allocation process requires management to make significant estimates and assumptions, especially with respect to intangible assets, estimated contingent consideration payments and pre-acquisition contingencies. Examples of critical estimates in valuing certain of the intangible assets we have acquired or may acquire in the future include but are not limited to: future expected cash flows from product sales, support agreements, consulting contracts, other customer contracts, and acquired developed technologies and patents; and discount rates utilized in valuation estimates. Unanticipated events and circumstances may occur that may affect the accuracy or validity of such assumptions, estimates or actual results. Additionally, any change in the fair value of the acquisition-related contingent consideration subsequent to the acquisition date, including changes from events after the acquisition date, such as changes in our estimates of relevant revenue or other targets, will be recognized in earnings in the period of the estimated fair value change. A change in fair value of the acquisition-related contingent consideration or the occurrence of events that cause results to differ from our estimates or assumptions could have a material effect on the consolidated financial position, statements of operations or cash flows in the period of the change in the estimate.

Note 2 - Summary of Significa32

Note 2 - Summary of Significant Accounting Policies: Impairment of Long-lived Assets (Policies)	12 Months Ended
	Dec. 31, 2016
Policies
Impairment of Long-lived Assets	Impairment of Long-Lived Assets Long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated future cash flows, an impairment charge is recognized in the amount by which the carrying amount of the asset exceeds the fair value of the asset. Assets to be disposed would be separately presented in the consolidated balance sheet and reported at the lower of the carrying amount or fair value less costs to sell, and are no longer depreciated. The assets and liabilities of a disposal group classified as held-for-sale would be presented separately in the appropriate asset and liability sections of the consolidated balance sheet, if material. No impairment losses have been realized for the periods presented.

Note 2 - Summary of Significa33

Note 2 - Summary of Significant Accounting Policies: Financial Instruments and Fair Values (Policies)	12 Months Ended
	Dec. 31, 2016
Policies
Financial Instruments and Fair Values	Financial Instruments and Fair Values The fair value of a financial instrument represents the amount at which the instrument could be exchanged in a current transaction between willing parties, other than in a forced or liquidation sale. Fair value estimates are made at a specific point in time, based upon relevant market information about the financial instrument. In determining fair value, we use various valuation methodologies and prioritize the use of observable inputs. We assess the inputs used to measure fair value using a three-tier hierarchy based on the extent to which inputs used in measuring fair value are observable in the market: Level 1 – inputs include exchange quoted prices for identical instruments and are the most observable. Level 2 – inputs include brokered and/or quoted prices for similar assets and observable inputs such as interest rates. Level 3 – inputs include data not observable in the market and reflect management judgment about the assumptions market participants would use in pricing the asset or liability. The use of observable and unobservable inputs and their significant in measuring fair value are reflected in our hierarchy assessment. The carrying amount of cash, prepaid assets, accounts payable and accrued liabilities approximates fair value due to the short-term maturities of these instruments. Because cash and cash equivalents are readily liquidated, management classifies these values as Level 1. The fair value of the debentures, approximate their book value as the instruments are short-term in nature and contain market rates of interest. Because there is no ready market or observable transactions, management classifies the debentures as Level 3.

Note 2 - Summary of Significa34

Note 2 - Summary of Significant Accounting Policies: Recently Issued Accounting Standards (Policies)	12 Months Ended
	Dec. 31, 2016
Policies
Recently Issued Accounting Standards	Recently Issued Accounting Standards In April 2015, the FASB issued ASU 2015-03, Simplifying the Presentation of Debt Issuance Costs, which relates to the financial statement presentation of debt issuance costs. This guidance requires debt issuance costs to be presented in the balance sheet as a reduction of the related debt liability rather than an asset. The guidance is effective for annual and interim periods beginning after December 15, 2015 and early adoption is permitted and will only result in a change in presentation of the costs on the balance sheet. In November 2015, the FASB issued ASU 2015-17, Balance Sheet Classification of Deferred Taxes. The guidance requires that all deferred tax assets and liabilities, along with any related valuation allowance, be classified as noncurrent on the balance sheet. The guidance becomes effective for annual reporting periods beginning after December 15, 2016 with early adoption permitted. The adoption of this guidance will only result in a change in the presentation of deferred taxes on the balance sheet.

Note 3 - Newco4pharmacy Trans35

Note 3 - Newco4pharmacy Transaction: Results of Operations Associated with Discontinued Operations Table Text Block (Tables)	12 Months Ended
	Dec. 31, 2016
Tables/Schedules
Results of Operations Associated with Discontinued Operations Table Text Block	For the Year ending December 31, 2015 Net Sales $ 464,786 Cost of sales 220,228 Gross Profit 244,558 Operating Expenses: Research and development 734,985 Selling, general and administrative 938,799 Total operating expenses 1,673,784 Operating Loss from Discontinued Operations (1,429,226) Other Expense: Interest expense, net (775,564) Disposal on fixed assets — Gain (Loss) on debt extinguishment 1,867,428 Net Loss from Discontinued Operations $ (337,362) Other Comprehensive Gain Net of Tax: Foreign currency translation adjustments 24,815 Comprehensive Loss from Discontinued Operations $ (312,547)

Note 8 - Stock Options_ Schedul

Note 8 - Stock Options: Schedule of Share-based Compensation, Stock Options, Activity (Tables)	12 Months Ended
	Dec. 31, 2016
Tables/Schedules
Schedule of Share-based Compensation, Stock Options, Activity	Shares Weighted- Average Exercise Price ($) Weighted- Average Remaining Contractual Term Aggregate Intrinsic Value ($) Outstanding at December 31, 2015 67,879 $ 21.40 7.17 — Granted 1,000,000 1.75 5.00 — Cancelled (1,000,000) 1.75 5.00 — Outstanding at December 31, 2016 67,879 $ 21.40 6.42 — Exercisable at December 31, 2016 67,879 $ 21.40 6.42 —

Note 9- Stock Warrants_ Warrant

Note 9- Stock Warrants: Warrants Table Text Block (Tables)	12 Months Ended
	Dec. 31, 2016
Tables/Schedules
Warrants Table Text Block	Shares Weighted- Average Exercise Price ($) Weighted- Average Remaining Contractual Term Outstanding at December 31, 2015 78,462 $ 29.55 3.43 Granted 66,666 2.50 2.00 Expired (2,475) 50.50 - Outstanding at December 31, 2016 142,653 $ 17.42 2.50 Exercisable at December 31, 2016 142,653 $ 17.42 2.50

Note 10 - Income Taxes_ Schedul

Note 10 - Income Taxes: Schedule of Effective Income Tax Rate Reconciliation (Tables)	12 Months Ended
	Dec. 31, 2016
Tables/Schedules
Schedule of Effective Income Tax Rate Reconciliation	2016 2015 Net tax loss carry-forwards $ 1,351,095 $ 03,893 Statutory rate 34% 34% Expected tax recovery 459,372 103,324 Change in valuation allowance (459,372) (103,324) Income tax provision $ - $ - Components of deferred tax asset: Non capital tax loss carry forwards $ 459,372 $ 103,324 Less: valuation allowance (459,372) (103,324) Net deferred tax asset $ - $ -

Note 1 - Organization, Basis 39

Note 1 - Organization, Basis of Presentation and Nature of Operations (Details)	1 Months Ended
	Jan. 31, 2016
Details
Stockholders' Equity, Reverse Stock Split	1 for 101

Note 3 - Newco4pharmacy Trans40

Note 3 - Newco4pharmacy Transaction: Results of Operations Associated with Discontinued Operations Table Text Block (Details)	12 Months Ended
	Dec. 31, 2015USD ($)
Details
Disposal Group, Including Discontinued Operation, Revenue	$ 464,786
Disposal Group, Including Discontinued Operation, Costs of Goods Sold	220,228
Disposal Group, Including Discontinued Operation, Gross Profit (Loss)	244,558
Disposal Group Including Discontinued Operation Research and Development	734,985
Disposal Group Including Discontinued Operation Selling General and Administrative	938,799
Disposal Group, Including Discontinued Operation, Operating Expense	1,673,784
Disposal Group, Including Discontinued Operation, Operating Income (Loss)	(1,429,226)
Interest Expense, Net	(775,564)
Gain (Loss) on debt extinguishment	1,867,428
Net loss from discontinued operations, net of tax	(337,362)
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax	24,815
Comprehensive Income Loss Discontinued Operations	$ (312,547)

Note 4 -deconsolidation of Ac41

Note 4 -deconsolidation of Acquisition (Details) - USD ($)	6 Months Ended	9 Months Ended	12 Months Ended
	Jun. 30, 2016	Sep. 30, 2016	Dec. 31, 2016
Deconsolidation, Gain (Loss), Amount			$ 1,618,200
Fair Value of Shares Issued Deconsolidation			$ 1,618,200
Restricted Stock | P3 Convertible Note
Conversion of Stock, Shares Issued			340,000
Conversion of Stock, Amount Issued		$ 1,183,200
Restricted Stock | VP of Corporate Development
Annual Salary OWed to Related Party	$ 125,000
Stock Issued During Period, Shares, Issued for Services	125,000
Stock Issued During Period, Value, Issued for Services	$ 435,000

Note 5 - Related Party Transa42

Note 5 - Related Party Transactions (Details) - USD ($)	1 Months Ended
	Dec. 31, 2016	Sep. 30, 2016	Sep. 23, 2016	May 25, 2016	Apr. 25, 2016	Jan. 25, 2016
Accounts payable - related party	$ 106,866
Two Board Members
Stock Issued During Period, Shares, Issued for Services						100,000
Stock Issued During Period, Value, Issued for Services						$ 145,000
Board Member
Stock Issued During Period, Shares, Issued for Services				100,000	1,000,000
Stock Issued During Period, Value, Issued for Services				$ 235,000	$ 47,680
Three New Directors
Stock Issued During Period, Shares, Issued for Services			100,000
Stock Issued During Period, Value, Issued for Services			$ 27,990
Former CFO
Monthly Professional Fees		$ 10,000
Shares Returned for Cancellation		2,000,000
Shares Used to Settle Obligation to Former Employee		100,000
Former CEO
Shares Cancelled from Stock Options		1,000,000
Shareholder
Monthly Professional Fees		$ 10,000
Consultant
Stock Issued During Period, Shares, Issued for Services	100,000
Stock Issued During Period, Value, Issued for Services	$ 19,080
Board of Directors
Stock Issued During Period, Shares, Issued for Services	100,000
Stock Issued During Period, Value, Issued for Services	$ 57,240

Note 6 - Debt (Details)

Note 6 - Debt (Details) - USD ($)	1 Months Ended					12 Months Ended
	Sep. 30, 2016	Jul. 31, 2016	May 31, 2016	May 19, 2016	Mar. 18, 2016	Dec. 31, 2016	Dec. 31, 2015	Jul. 11, 2016	Nov. 30, 2014	Aug. 31, 2014
Short Term Convertible Note								$ 48,000
Short Term Convertible Note Carrying Value						$ 45,175
Debt Discount						21,500
Amortized Debt Discount						21,500
Beneficial conversion feature		$ 32,541	$ 25,146			67,062
Convertible Note A
Debt Instrument, Annual Principal Payment					$ 60,000
Weighted Average Number of Shares, Restricted Stock					15,000
Deposit Liabilities, Accrued Interest						3,660
Value of Common Shares Issued					$ 18,750
Beneficial Conversion Feature						9,375
Amortization of Debt Discount (Premium)						28,125
Convertible Note B
Deposit Liabilities, Accrued Interest	$ 3,671
Amortization of Debt Discount (Premium)				$ 100,000
Convertible Debentures Face Value	$ 100,000			$ 100,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross				66,666
Value of Warrants				$ 103,086
Interest Expense, Debt				$ 3,086
Shares Issued for Cancellation of Debt to Lender	400,000
Value of Shares Issued for Cancellation of Debt	$ 120,000
Loss on Debt Extinguishment						16,329
August 2014 Convertible Debentures (Series C)
Deposit Liabilities, Accrued Interest						24,420
Convertible Debentures Face Value										$ 100,000
Convertible Debentures Carrying Value						110,833				$ 110,833
Debt Conversion, Original Debt, Interest Rate of Debt							10.00%
Debt Instrument, Convertible, Conversion Price							$ 20.20
Class of Warrant or Right, Number of Securities Called by Warrants or Rights							4,950
Class of Warrant or Right, Exercise Price of Warrants or Rights							$ 20.20
November 2014 Convertible Debentures (Series D)
Deposit Liabilities, Accrued Interest						2,941
Convertible Debentures Face Value									$ 10,000
Convertible Debentures Carrying Value						$ 11,333			$ 11,333
Debt Conversion, Original Debt, Interest Rate of Debt							12.00%
Debt Instrument, Convertible, Conversion Price							$ 16.67
Class of Warrant or Right, Number of Securities Called by Warrants or Rights							495
Class of Warrant or Right, Exercise Price of Warrants or Rights							$ 20.20

Note 7 - Stockholders' Deficit

Note 7 - Stockholders' Deficit (Details) - USD ($)	1 Months Ended	12 Months Ended
	Sep. 30, 2016	Dec. 31, 2016	Dec. 31, 2015
Proceeds from Issuance or Sale of Equity		$ 60,000
Gross Proceeds from Sale of Common Stock Shares		120,000
Sale of Stock, Price Per Share		$ 0.50
Payments of Stock Issuance Costs		$ 9,000
Accrued interest		$ 31,021	$ 14,918
Restricted Stock
Stock Issued During Period, Shares, Issued for Services		4,070,000
Stock Issued During Period, Value, Issued for Services		$ 3,377,735
Convertible Promissory Note A
Weighted Average Number of Shares, Restricted Stock		15,000
Convertible Debentures Face Value		$ 18,750
Common Shares
Common stock issued for satisfaction of payables, Shares		1,066,666
Common stock issued for satisfaction of payables, Value		$ 580,000
Loss on Conversion of Acocunts Payable to Shares		190,000
Shares Issued for Conversion Of Debt
Conversion of Loan	$ 100,000
Shares Issued for Cancellation of Debt to Lender	400,000
Value of Shares Issued for Cancellation of Debt	$ 100,000
Accrued interest	$ 3,671
Debt Beneficial Conversion Feature
Proceeds from Issuance or Sale of Equity		201,780
Beneficial Conversion Feature		67,062
Stock Payable for Debt
Stock Payable Outstanding		$ 10,000

Note 8 - Stock Options (Details

Note 8 - Stock Options (Details)	1 Months Ended	12 Months Ended
	Jan. 31, 2016	Dec. 31, 2015
Stockholders' Equity, Reverse Stock Split	1 for 101
Warrant
Stockholders' Equity, Reverse Stock Split		1 for 101

Note 8 - Stock Options_ Sched46

Note 8 - Stock Options: Schedule of Share-based Compensation, Stock Options, Activity (Details) - $ / shares	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Details
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number	67,879	67,879
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price	$ 21.40	$ 21.40
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term	6 years 5 months 1 day	7 years 2 months 1 day
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures	1,000,000
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price	$ 1.75
Share Based Compensation Arrangement by Share Based Payment Award Options Granted Weighted Average Remaining Contractual Term2	5 years
Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period	(1,000,000)
Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price	$ 1.75
Share Based Compensation Arrangement by Share Based Payment Award Options Expired Weighted Average Remaining Contractual Term2	5 years
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number	67,879
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price	$ 21.40
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Exercisable Options, Weighted Average Remaining Contractual Term	6 years 5 months 1 day

Note 9- Stock Warrants_ Warra47

Note 9- Stock Warrants: Warrants Table Text Block (Details) - $ / shares	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number	67,879	67,879
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price	$ 21.40	$ 21.40
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term	6 years 5 months 1 day	7 years 2 months 1 day
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures	1,000,000
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price	$ 1.75
Share Based Compensation Arrangement by Share Based Payment Award Options Granted Weighted Average Remaining Contractual Term2	5 years
Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period	(1,000,000)
Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price	$ 1.75
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number	67,879
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price	$ 21.40
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Exercisable Options, Weighted Average Remaining Contractual Term	6 years 5 months 1 day
Warrants
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number	142,653	78,462
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price	$ 17.42	$ 29.55
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term	2 years 6 months	3 years 5 months 5 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures	66,666
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price	$ 2.50
Share Based Compensation Arrangement by Share Based Payment Award Options Granted Weighted Average Remaining Contractual Term2	2 years
Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period	(2,475)
Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price	$ 50.50
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number	142,653
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price	$ 17.42
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Exercisable Options, Weighted Average Remaining Contractual Term	2 years 6 months

Note 10 - Income Taxes_ Sched48

Note 10 - Income Taxes: Schedule of Effective Income Tax Rate Reconciliation (Details) - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Details
Deferred Tax Assets, Operating Loss Carryforwards	$ 1,351,095	$ 3,893
Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate	34.00%	34.00%
Expected Tax Recovery	$ 459,372	$ 103,324
Deferred Tax Assets, Valuation Allowance, Current	(459,372)	(103,324)
Non Capital Tax Loss Carry Forwards	459,372	103,324
Deferred Tax Assets, Valuation Allowance	$ (459,372)	$ (103,324)

Note 11 - Commitments and Con49

Note 11 - Commitments and Contingencies (Details) - USD ($)	12 Months Ended
	Dec. 31, 2015	Sep. 23, 2016	Jul. 06, 2016
Details
Loss Contingency, Damages Sought, Value	$ 177,270
Loss Contingency Damages Sought Value Interest Rate	12.00%
Loss Contingency Accrual		$ 75,000
Commitments and Contingencies Reserve			$ 280,000